Next, we validated this observation by performing immunofluorescence analysis in clinical GBM patients’ specimens and observed that SH3KBP1 are markedly co-expressed with SOX2, which is a known GSCs marker (Figures 2F, G). Here, SH3KBP1 is linked to glioblastoma.